Author

B. Kruspig

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1

Frequent Co-Authors

C. Nixon· 3 shared C. Miller· 2 shared D. J. Murphy· 2 shared K. Kirschner· 2 shared R. Shaw· 2 shared S. B. Coffelt· 2 shared S. Laing· 2 shared Y.-C. Hsieh· 2 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Nixon

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

γδ T cells impair airway macrophage differentiation in lung adenocarcinoma

X. L. Raffo-Iraolagoitia, A. J. McFarlane, B. Kruspig, F. Fercoq, J. Secklehner, M. De Donatis, J. B. G. Mackey, R. Wiesheu, S. Laing, Y.-C. Hsieh, R. Shaw, R. Corbyn, C. Nixon, C. Miller, K. Kirschner, , L. M. Carlin

The paper identifies that CD27+ γδ T cells impair the differentiation of tumor-associated macrophages into airway macrophages in lung adenocarcinoma.

bioRxiv · Sep 14, 2023Immunology

ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinoma

S. Laing, B. Kruspig, R. Shaw, L. Officer-Jones, S. Edwards, D. McKinven, Y.-C. Hsieh, I. Powley, N. Brady, R. Pennie, R. Kwan, A. Lima, S. Myrta, M. Periyasamy, I. C. Dye, , D. J. Murphy

The paper investigates how ERBB signaling contributes to immune evasion in KRAS-driven lung adenocarcinoma using a novel mouse model and finds that transient ERBB blockade can restore immune surveillance when combined with PD1 blockade.

bioRxiv · Jul 24, 2023 · PreprintCancer Biology

The ERBB network facilitates KRAS-driven lung tumorigenesis

B. Kruspig, T. Monteverde, S. Neidler, A. Hock, E. Kerr, C. Nixon, W. Clark, A. Hedley, C. Dick, K. Vousden, C. Martins, D. Murphy

This study shows that the ERBB network is required for KRAS-driven lung tumorigenesis and that inhibiting it enhances MEK inhibitor efficacy in treating such cancers.

bioRxiv · Apr 9, 2018Cancer Biology